TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06333743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser ablation
Description: Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP or Conization
Description: The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
Study: NCT04719507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block
Description: ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block
Description: ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Only Product in Parenteral Dose Form
Description: pethidine (1 mg/kg ) once
Study: NCT05369455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided caudal block
Description: determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
Study: NCT05639374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS_HealthyClassroom
Description: First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
Study: NCT04830020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMW-HA
Description: Aerolized administration b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMW-HA
Description: Aerolized administration b.i.d.
Study: NCT06122129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexible ureteroscope with ureteral access sheath
Description: The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible ureteroscope without ureteral access sheath
Description: Ureteroscopy will be carried out without a ureteral access sheath
Study: NCT04906044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab combined withTotal Neoadjuvant Treatment
Study: NCT05741567

Intervention type: PROCEDURE
Intervention: correction of anterior prolapse
Description: percentage of failed prolapse correction
Study: NCT05502393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS107
Description: JS107, i.v., q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS107
Description: JS107, i.v., q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab i.v., q3w
Study: NCT05111158

Intervention type: DIAGNOSTIC_TEST
Intervention: mfERG
Description: mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)

Intervention type: DIAGNOSTIC_TEST
Intervention: mfERG
Description: mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
Study: NCT05967611

Intervention type: DIAGNOSTIC_TEST
Intervention: Trendelenburg hip abduction test
Description: The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
Study: NCT06147310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Group
Description: The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
Study: NCT05451173

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
Study: NCT05553977

Intervention type: DRUG
Intervention: Bowel preparation for colonoscopy
Description: one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy will be performed to every patient included in the study
Study: NCT05819021

Intervention type: DEVICE
Intervention: SAINT® Neuromodulation System (NMS)
Description: The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
Study: NCT06217523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics-directed Hyperlipidaemia Management
Description: Pharmacogenomics-directed Hyperlipidaemia Management
Study: NCT05743179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
Study: NCT04913025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 60-minute IV infusion, as a flat dose of 480mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 60-minute IV infusion, as a flat dose of 480mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 60-minute IV infusion, as a flat dose of 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 60-minute IV infusion, as a flat dose of 400mg
Study: NCT05620563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05513079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy Based Counseling
Description: The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
Study: NCT06495164

Intervention type: DRUG
Intervention: Palbociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Intervention: Palbociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor
Study: NCT05629975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements
Description: Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days.
Study: NCT06582719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPT-based counseling
Description: AI-based counseling provided to the patient, accessible on their smartphone device at the time of Gestational Diabetes diagnosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Standard Nutritional Counselling provided by a registered dietician at the time of Gestational Diabetes diagnosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Standard Nutritional Counselling provided by a registered dietician at the time of Gestational Diabetes diagnosis
Study: NCT05856331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR447537
Description: A1PI, Recombinant, Bivalent Fc Fusion Protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR447537
Description: A1PI, Recombinant, Bivalent Fc Fusion Protein

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemaira
Description: Alpha1-Proteinase Inhibitor (Human)
Study: NCT06254482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC518
Description: PTC518 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC518
Description: PTC518 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC518
Description: PTC518 will be administered per dose and schedule specified in the arm.
Study: NCT05555823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002
Description: 300 mg tablets for oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablets for oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repaglinide
Description: 0,5 mg tablets for oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Description: 100 mg capsules for oral intake
Study: NCT06495164

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor

Intervention type: DRUG
Intervention: Ribociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Intervention: Abemaciclib
Description: CDK4/6 inhibitor
Study: NCT05897905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised, holistic follow-up appointments underpinned by self determination theory
Description: Appointment 1 (two weeks after discharge):~* Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~* Detailed biopsychosocial review.~* Understand participant priorities and jointly set goals.~* Agreeing onward referrals if needed.~* Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~* Review priorities identified in post stroke review checklist.~* Review goals and plans from first appointment.~* Address any new or persistent information gaps.~* Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~* Agreeing onward referrals and action plan.~* Written summary and plan sent to GP.
Study: NCT06050304

Intervention type: BEHAVIORAL
Intervention: Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter
Description: In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).

Intervention type: BIOLOGICAL
Intervention: 3 blood tests
Description: We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
Study: NCT05738044

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06525103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electromagnitic field therapy
Description: EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology.~* Frequency : 50 or 60 Hz.~* Intenisty: 0-100 .Input voltage: 230 V

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: Crazy fit machine.~* Input voltage:220 V.~* Frequency : 30 Hz.~* Maximum power: 1500W.~* Intensity:1 to 50 levels.
Study: NCT06413043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
Study: NCT05798910

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALS VR (VR based serious gaming module for advanced life support training)
Description: Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture based training for advanced life support
Description: Taking part in a classical lecture about advanced life support.
Study: NCT05870579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NeoB
Description: \[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening, potentially at Cycle 2 Day 15 visit, and between 4 and 8 weeks after the last administered dose of \[177Lu\]Lu-NeoB.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NeoB
Description: Study participants will receive \[177Lu\]Lu-NeoB once every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg once daily (OD) days 1 to 21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For pre/peri-menopausal women and men only.
Study: NCT06162195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The H1 Implant
Description: Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless total hip replacement
Description: Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
Study: NCT05973786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: ATC code: N06AB10
Study: NCT04874350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1148
Description: LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo capsule
Study: NCT05973786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: See arm description
Study: NCT06027970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline (NS)
Description: After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
Study: NCT05818852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Capsules for oral administration.
Study: NCT05405582

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Community-based differentiated HIV prevention incl.PrEP with SRH
Description: Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Health Clinic based HIV prevention and care
Description: Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
Study: NCT05520515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Training Plus Health Education
Description: Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
Study: NCT05818852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Capsules for oral administration.
Study: NCT05973786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate acid
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate acid
Description: See arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: See arm description
Study: NCT04533542

Intervention type: OTHER
Intervention: Measurement
Description: Undergo sensory measurements

Intervention type: OTHER
Intervention: Measurement
Description: Undergo sensory measurements

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05818852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548 Placebo
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-548 Placebo
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-548 Placebo
Description: Tablets for oral administration.
Study: NCT04620252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive supplement
Description: Chewable candy (negative control), chewed for 30 seconds.